{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:14:12Z","timestamp":1792084452270,"version":"4.4.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"},{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"},{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/14740338.2022.2047177","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T03:34:10Z","timestamp":1646192050000},"page":"1113-1120","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer\u2019s safety database"],"prefix":"10.1080","volume":"21","author":[{"given":"Rose","family":"O\u2019Flynn","sequence":"first","affiliation":[{"name":"Merck & Co. Inc","place":["Kenilworth, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Kenilworth, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty","family":"Waskin","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Kenilworth, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Leong","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Kenilworth, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Straus","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Kenilworth, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3901-y"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2017.05.005"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562902"},{"key":"e_1_3_7_9_1","unstructured":"Assasi N Grobelna A CADTH Rapid Response Reports. Posaconazole for the prophylaxis and treatment of invasive aspergillosis: a review of clinical effectiveness and guidelines. Version 1. July 13 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/htis\/2017\/RD0040_Posaconazole%20for%20Invasive%20Aspergillosis_Final.pdf. cited 2021 May 12."},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv380"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx263"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S162964"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i8.601"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.10.029"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1270264"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1199272"},{"key":"e_1_3_7_19_1","unstructured":"Noxafil (posaconazole) injection for intravenous use. Noxafil (posaconazole) delayed-release tablets for oral use. Noxafil (posaconazole) oral suspension. Whitehouse Station NJ: Merck Sharp & Dohme Corp.; 2021."},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00188-17"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12871"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx122"},{"key":"e_1_3_7_23_1","first-page":"247","article-title":"Evaluation of neural tube defects (NTDs) after exposure to raltegravir during pregnancy","volume":"2019","author":"Shamsuddin H","year":"1999","unstructured":"Shamsuddin H, Raudenbush CL, Sciba BL, et al. Evaluation of neural tube defects (NTDs) after exposure to raltegravir during pregnancy. J Acquir Immune Defic Syndr. 1999;2019:247\u2013250.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz295"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.013"},{"key":"e_1_3_7_26_1","unstructured":"MedDRA. What\u2019s new. MedDRA version 21.1. 9\/2018;14. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english. cited 2021 May 12."},{"key":"e_1_3_7_27_1","unstructured":"US Department of health and human services. Guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines. 2001;1\u201350. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Draft-Guidance-for-Industry\u2013Postmarketing-Safety-Reporting-for-Human-Drug-and-Biological-Products-Including-Vaccines.pdf. cited 2021 May 12."},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.05.007"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.02.015"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04035-14"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12452"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12023"},{"key":"e_1_3_7_33_1","volume-title":"The future of drug safety: promoting and protecting the health of the public","author":"Institute of Medicine","year":"2007","unstructured":"Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. The National Academies Press: Washington, DC; 2007."}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2022.2047177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:07:15Z","timestamp":1770390435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2022.2047177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/14740338.2022.2047177"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2022.2047177","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}